# Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

> **NCT02959879** · PHASE2 · COMPLETED · sponsor: **University Hospital, Rouen** · enrollment: 153 (actual)

## Conditions studied

- Resectable Pancreatic Duct Adenocarcinoma

## Interventions

- **DRUG:** FOLFOX neoadjuvant chemotherapy
- **DRUG:** FOLFIRINOX neoadjuvant chemotherapy
- **PROCEDURE:** curative surgery for resectable pancreatic duct adenocarcinoma
- **DRUG:** Standard adjuvant chemotherapy
- **DRUG:** adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT02959879
- **Lead sponsor:** University Hospital, Rouen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2023-08-08
- **Final completion:** 2023-08-08
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2026-02-06

## Collaborators

- UNICANCER
- Federation Francophone de Cancerologie Digestive
- Federation of Research in Surgery (FRENCH)
- GERCOR - Multidisciplinary Oncology Cooperative Group

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959879, "Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02959879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*